- Home
- COF vs VRTX Comparison
COF vs VRTX Comparison
Compare COF & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COF
- VRTX
- Stock Information
- Founded
- COF 1988
- VRTX 1989
- Country
- COF United States
- VRTX United States
- Employees
- COF N/A
- VRTX N/A
- Industry
- COF Major Banks
- VRTX EDP Services
- Sector
- COF Finance
- VRTX Technology
- Exchange
- COF Nasdaq
- VRTX Nasdaq
- Market Cap
- COF 136.1B
- VRTX 115.6B
- IPO Year
- COF 1994
- VRTX 1991
- Fundamental
- Price
- COF $221.22
- VRTX $395.12
- Analyst Decision
- COF Buy
- VRTX Buy
- Analyst Count
- COF 15
- VRTX 24
- Target Price
- COF $236.73
- VRTX $496.76
- AVG Volume (30 Days)
- COF 3.5M
- VRTX 2.5M
- Earning Date
- COF 07-22-2025
- VRTX 08-04-2025
- Dividend Yield
- COF 1.08%
- VRTX N/A
- EPS Growth
- COF N/A
- VRTX N/A
- EPS
- COF N/A
- VRTX 14.07
- Revenue
- COF $23,773,000,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- COF $94.55
- VRTX $10.40
- Revenue Next Year
- COF $18.10
- VRTX $10.63
- P/E Ratio
- COF N/A
- VRTX $28.25
- Revenue Growth
- COF N/A
- VRTX 10.46
- 52 Week Low
- COF $131.55
- VRTX $362.50
- 52 Week High
- COF $232.45
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- COF 59.54
- VRTX 40.50
- Support Level
- COF $209.40
- VRTX $388.93
- Resistance Level
- COF $217.20
- VRTX $400.94
- Average True Range (ATR)
- COF 5.06
- VRTX 12.97
- MACD
- COF 0.28
- VRTX 1.12
- Stochastic Oscillator
- COF 91.55
- VRTX 62.28
About COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.